Shenzhen Kangtai Biological Products Co Ltd
300601.SZ- Latest Trade
- trading higher42.34CNY
- Change
- 0.38
- % Change
0.91%Positive
- Day Range
- 41.89 - 42.89
- 52-Week Range
- 34.76 - 99.37
As of Jun 25 2022. Values delayed up to 15 minutes
- Previous Close
- 41.96
- Open
- 42.18
- Volume
- 11,575,261.00
- 3 Month Average Trading Volume
- 241.29
- Shares Out (Mil)
- 1,120.49
- Market Cap
- 47,015.64
- Forward P/E
- 30.75
- Dividend Yield
- 1.71
Key Statistics
1.53333333 mean rating - 15 analysts
- P/E Excl. Extra Items (TTM)
- 30.98
- Price To Sales (TTM)
- 11.07
- Price To Book (Quarterly)
- 4.69
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 24.19
- Long Term Debt/Equity (Quarterly)
- 19.38
- Return On Investment (TTM)
- 14.77
- Return On Equity (TTM)
- 12.38
2021 (millions USD)
About Shenzhen Kangtai Biological Products Co Ltd
Company Information
Shenzhen Kangtai Biological Products Co.,Ltd. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The Company operates its businesses primary in domestic market.
Address
No. 10 Shutianpu Road Matian Neighborhood, Guangming DistrictSHENZHEN, GNG
518106
China
Industry
Biotechnology & Drugs
Executive Leadership
- Weimin Du
- Chairman of the Board
- Xiang Miao
- President, Director
- Haifa Zheng
- Vice Chairman of the Board, Vice President
- Feidong Wen
- Vice Chairman of the Board
- Hui Zhou
- Chief Financial Officer
- Jiankai Liu
- Vice President, Director
- Jin Tao
- Secretary of the Board
- Keping Hu
- Independent Director
- Jiaoyu Li
- Independent Director
- Zhiquan Luo
- Independent Director
Latest News
- WorldChina builds new plant for IMBCAMS COVID-19 vaccine -state media
China is building a new COVID-19 vaccine factory that is capable of boosting annual production of a shot developed by a medical research institute to between 500 million and 1 billion doses, state-backed media said on Wednesday.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes